Flow-Gradient Patterns can help in the selection of patients with aortic stenosis

Original title: Flow-Gradient Patterns in Severe Aortic Stenosis UIT Preserved Ejection Fraction. Clinical Characteristic and Predictos of Survival. Reference: Eleid, M, et al. Circulation 2013;128:1781-1789

Severe aortic stenosis is usually defined by echocardiography as a 40 mm mean transvalvular gradient Hg at >4 m/s; but there are low flow or paradoxical low flow cases with different evolution.

1704 AS patients were divided in 4 groups: low flow/high gradient (LF/HG) n= 50 (3%), low flow/low gradient (LF/LG) n= 53 (3%), normal flow/low gradient (NF/LG) n= 352 (21%) and normal flow/high gradient (NF/HG) n= 1249 (73%).

The less symptomatic was the NF/LG) group, characterized by a high prevalence of women, less, smaller LV cavity and restrictive filling pattern. The LF/LG group presented the most deteriorated LVEF, also the lowest LV mass index, the smallest LV diameter and the greatest incidence of auricular fibrillation.

62% of all patients received surgical AVR and 4% received TAVR. NF/LG patients mostly received medical management, with favorable survival of 59% at 2 years.

The LF/LG group had the worst prognosis, with 60% survival rate at 2 years. Survival rate was 85% for the NF/LG group, 82% for the NF/HG group and 78% for the LF/LG group (p<0.0001 was the difference in survival between groups).  Aortic valve replacement (AVR) was associated with a 69% mortality reduction in LF/LG and NF/HG groups.

Conclusion:

NF/LG severe AS with preserved EF exhibits favorable survival with medical management and impact of AVR on survival was neutral. LF/LG was associated with higher mortality and TAVR was associated with improved survival. 

Editorial Comment

This new way of classifying AS offers important information about prognosis. It would be preferable to start using it on a daily basis, especially with high risk patients that most frequently pose the greatest challenges as regards strategy.

Courtesy of Dr Carlos Fava.
Interventional Cardiologist.
Favaloro Foundation. Argentina.

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....